Holen Sie sich die Stockscreener-App
351.82
4.96%
16.63
Handel nachbörslich:
351.49
-0.33
-0.09%
Schlusskurs vom Vortag:
$335.19
Offen:
$339
24-Stunden-Volumen:
537.02K
Relative Volume:
1.33
Marktkapitalisierung:
$10.37B
Einnahmen:
$417.30M
Nettoeinkommen (Verlust:
$225.03M
KGV:
47.03
EPS:
7.4815
Netto-Cashflow:
$237.38M
1W Leistung:
+3.71%
1M Leistung:
-5.49%
6M Leistung:
+26.85%
1J Leistung:
+138.34%
1-Tages-Spanne:
$334.38
$358.00
1-Wochen-Bereich:
$325.00
$358.00
52-Wochen-Spanne:
$130.50
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
351.82 | 9.88B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech Inc (KRYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech, Inc. Revenue Breakdown – NASDAQ:KRYS - TradingView
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Price, News, Quote & History - Yahoo! Finance Canada
KRYS|Krystal Biotech Inc|Price:335.190|Chg%:+7.690 - TradingKey
Krystal Biotech, Inc. (KRYS) stock price, news, quote and history - Yahoo Finance UK
Krystal Biotech Inc (KRYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400Biotechnology - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 Health Care - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 Health Care - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 - marketscreener.com
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 - The Manila Times
Krystal Biotech sets Aug. 3 webcast before U.S. markets open - Stock Titan
Krystal Biotech Reveals Single-Patient Data from Discontinued KB801 Trial in Patent Filing - Kalkine Media
Krystal BiotechFiles Response With Uspto On Kb801 Patent ApplicationSEC Filing - TradingView
Why Tutor Perini Stock Trounced the Market on Tuesday - The Motley Fool
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech (KRYS) Joins S&P MidCap 400 Amid Index Changes - GuruFocus
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Finansavisen
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a $10 Billion Valuation and Strategic Growth in Genetic Medicine - DirectorsTalk Interviews
(KRYS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
KRYS Jumps As Wall Street Hikes Price Targets On Vyjuvek Momentum - StocksToTrade
KRYS Jumps As Analysts Race To Lift Price Targets - StocksToTrade
KRYS Jumps As Wall Street Lifts Bullish Price Targets - StocksToTrade
Krystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalysts - Quiver Quantitative
Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup - ChartMill
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396 - Moomoo
ETFs Investing in Krystal Biotech, Inc. Stocks - TradingView
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $369.44, Implies 1% Upside - TradingView
Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474 - Moomoo
BofA raises Krystal Biotech stock price target on Vyjuvek growth By Investing.com - Investing.com Nigeria
BofA raises Krystal Biotech stock price target on Vyjuvek growth - Investing.com
Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts - Sahm
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Is the options market predicting a spike in Krystal Biotech stock? - MSN
Here's why Krystal Biotech, Inc. (KRYS) is a strong momentum stock - MSN
Analysts see more upside for Abivax, Krystal Biotech, Marvell - MSN
3 Soaring Stocks That May Have More Upside Ahead - The Globe and Mail
Krystal Biotech focuses on gene-based dermatology treatments as investors watch long-term growth - ad-hoc-news.de
Krystal Biotech, Inc. (KRYS) Stock Analysis: A High-Potential Biotech with Robust Revenue Growth and Strategic Therapeutic Pipeline - DirectorsTalk Interviews
KRYSKrystal Biotech Inc Options - Finviz
Price to book forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Krystal Biotech stock soars 16% in three months: Here's why - MSN
Krystal Biotech (KRYS) soars 3.4%: Is further upside left in the stock? - MSN
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):